Merrill rates Regeneron neutral

Regeneron Pharmaceuticals Inc. was given a neutral rating by Merrill Lynch analyst Hari Sambasivam. The company reported third-quarter revenues of $15.6 million, compared to the analyst's estimate of $17.1 million. Regeneron reported total expenses of $43.9 million, higher than Merrill's estimate of $34.8 million. Sambasivam's revised loss-per-share estimates for 2006-2008 are now $1.67, $1.05 and $0.89 from $1.79, $1.73 and $1.77. Shares of the Tarrytown, N.Y.-based biotechnology company were up $1.26, or 5.20%, at $22.98. (Nasdaq: REGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.